Loading...
OTCMSHJBF
Market cap3.06bUSD
Dec 31, Last price  
1.97USD
Name

Shanghai Junshi Biosciences Co Ltd

Chart & Performance

D1W1MN
OTCM:SHJBF chart
P/E
—
P/S
20.87
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.36%
Rev. gr., 5y
337.82%
Revenues
1.50b
+3.38%
5,801,8862,886,7923,757,0001,148,000934,000775,089,0001,594,897,0004,024,841,0001,453,493,0001,502,550,000
Net income
-2.28b
L-11.64%
-25,253,952-57,970,317-131,967,000-321,071,000-716,414,000-744,233,000-1,665,639,000-728,181,000-2,582,095,000-2,281,624,000
CFO
-2.01b
L+13.50%
-39,189,540-82,027,829-185,207,000-347,076,000-510,758,000-1,187,034,000-1,498,806,000-641,901,000-1,775,325,000-2,014,964,000

Profile

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
URL
https://www.junshipharma.com/
IPO date
Dec 24, 2018
Employees
2,772
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,502,550
3.38%
1,453,493
-63.89%
Cost of revenue
4,005,924
4,204,628
Unusual Expense (Income)
NOPBT
(2,503,374)
(2,751,135)
NOPBT Margin
Operating Taxes
43,995
(93,107)
Tax Rate
NOPAT
(2,547,369)
(2,658,028)
Net income
(2,281,624)
-11.64%
(2,582,095)
254.60%
Dividends
(19,158)
Dividend yield
0.04%
Proceeds from repurchase of equity
125,704
3,831,422
BB yield
-0.66%
-8.61%
Debt
Debt current
575,322
435,414
Long-term debt
1,266,627
976,416
Deferred revenue
121,615
Other long-term liabilities
370,614
7,504
Net debt
(3,069,305)
(5,987,942)
Cash flow
Cash from operating activities
(2,014,964)
(1,775,325)
CAPEX
(832,575)
(393,952)
Cash from investing activities
(892,422)
(467,619)
Cash from financing activities
681,041
4,643,009
FCF
(3,228,675)
(2,453,153)
Balance
Cash
3,778,142
5,996,936
Long term investments
1,133,112
1,402,836
Excess cash
4,836,126
7,327,097
Stockholders' equity
(8,047,058)
1,275,706
Invested Capital
17,509,688
9,934,057
ROIC
ROCE
EV
Common stock shares outstanding
985,302
917,465
Price
19.44
-59.92%
48.50
-16.38%
Market cap
19,154,274
-56.95%
44,497,061
-14.06%
EV
16,254,356
38,870,361
EBITDA
(2,200,154)
(2,457,481)
EV/EBITDA
Interest
29,006
29,370
Interest/NOPBT